Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
Findings published in
Cell have revealed that a rarely studied type of genetic material – known as circular RNA – is prevalent in prostate cancer and some of this genetic material is essential for growth of the cancer.
The work was carried out in the labs of Drs.
Housheng Hansen He at the Princess Margaret Cancer Centre and
Paul Boutros at the University of California, Los Angeles, who was formerly at the Ontario Institute of Cancer Research.
"Novel sequencing approaches have opened up a new realm of research," says Dr. He, lead author of the study. "By studying this circular genetic material in prostate cancer, we've uncovered a wealth of insight into how the cancer grows and spreads, while uncovering potential new strategies to target and kill it."
The main type of genetic material in the cell – known as genomic DNA – serves as the "source book" that holds the information required by cells to carry out chemical reactions required for life. DNA is also used by the cell to create or "code for" other forms of genetic material, including RNA, which is thought of as the "working copy" of the genetic code.
Much of the DNA and RNA found in the cell resembles a string or rope of varying lengths; however, some of it can be joined end to end to create a circular molecule.
Dr. He and his collaborators began to suspect that circular RNA may be important for prostate cancer growth because previous studies have suggested that various distinct forms of RNA are present in prostate cancer cells. As well, circular RNA has been implicated in other types of cancers, such as colon and breast cancer.
The researchers used a technique known as ultra-deep sequencing to define the circular RNA present within 144 tumours from patients with prostate cancer. They identified over 76,000 circular RNAs – more than 30,000 of which had not been previously described.
The researchers then compared the genetic data to patient outcomes, revealing that tumours from individuals with the most aggressive types of prostate cancer tended to have aberrant production of circular RNAs.
The researchers took this work one step further by targeting and inhibiting specific circular RNA molecules in experimental models of prostate cancer. They found that about 11 per cent of the circular RNA was important for driving cancer growth – emphasizing its potential to serve as a new anticancer target.
This work was supported by the Princess Margaret Cancer Foundation, the Princess Margaret Genomic Centre, the Ontario Institute for Cancer Research, Prostate Cancer Canada, Terry Fox Research Institute, the Canada Foundation for Innovation, the Ontario Research Fund, the Natural Sciences and Engineering Research Council of Canada, the Canadian Cancer Society, the Canadian Institutes of Health Research, the Shanghai Committee of Science and Technology, University of Toronto and The Center for Translational Molecular Medicine.
Read more about the study